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The transfemoral aortic valve implantation 
(TF-AVI) is increasingly embraced as a viable 
technique for aortic valve replacement (AVR) 
in selected high-risk patients. The positioning 
and implantation of valve prosthesis is normally 
based on landmarks identified preoperatively by 
a cardiac CT scan, aortic and coronary angiog-
raphy and confirmed intraoperatively by fluoros-
copy and injections of contrast medium. Aortic 
annulus diameter, valve leaflets anatomy, pattern 
of calcifications, distance between the annulus 
and the coronary ostia are useful landmarks [1]. 
Transesophageal echocardiography (TEE) is use-
ful for final measurements and control of valve 
functioning intraoperatively [2]. After admin-
istration of contrast medium, patients with 
chronic renal insufficiency selected for transcath-
eter AVR are exposed to a higher risk of acute 
postoperative renal failure [3,4], which increases 
the risk of postoperative mortality [5], so every 
effort should be made to reduce the quantity of 
contrast. Indeed, moderate-to-severe renal insuf-
ficiency with serum creatinine levels >3 mg/dl 
was an exclusion criteria in the recently published 
PARTNER Trial [6]. Cases of aortic valve implan-
tation through the transapical approach [7,8] and 
endovascular aortic repair [9] without contrast 
medium use have been reported. However, we are 
not aware of published cases of TF-transcatheter 
aortic valve implantation (TAVI) without 
the intraoperative administration of contrast 
medium.
We reported a case of TF-TAVI under fluor-
oscopy and echocardiographic control without 
contrast media in a patient with severe renal 
failure as a consequence of multiorgan failure.
Case report
A 77-year-old female with a known history of 
severe aortic valve stenosis (aortic orifice area 
of 0.6 cm2/m2, peak gradient 45 mmHg), 
coronary artery disease (1-drug-eluting stent 
in the left anterior descending [LAD] artery, 
another in the circumflex artery), diabetes, 
chronic severe renal failure and liver failure 
was admitted in profound cardiogenic shock. 
During transportation, the emergency medical 
services reverted several episodes of sustained 
ventricular tachycardia with DC shocks.
On admission, blood pressure was 
65/40 mmHg with atrial fibrillation; left ven-
tricular ejection fraction was 14%, creatinine 
kinase isoenzyme MB: 63 µg/l (upper nor-
mal limit: <5); TnI: 33.2 µg/l (<0.5); serum 
creatinine:  4.7 mg/dl without dialysis; total 
plasma-bilirubin: 44.3 µmol/l (1–17); and 
serum alkaline phosphatase: 1900 U/l (5–40). 
An emergency aortic balloon-valvuloplasty 
was performed through the left femoral artery 
(14 Fr) with a 25 mm balloon. The trans valvular 
gradient reduced from 33 to 5 mmHg, blood 
pressure raised to 95/60 mmHg, while heart rate 
decreased to 100 bpm without significant aortic 
regurgitation by TTE. Subsequently, coronary 
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Transfemoral aortic valve implantation has recently emerged as a therapeutic 
option for patients with symptomatic, severe aortic stenosis for whom standard 
surgical aortic valve surgery is not suitable. Aortic valvuloplasty and valve 
positioning is normally performed under fluoroscopy and requires several injections 
of contrast medium. In critically ill patients with advanced renal insufficiency, 
contrast media administration can further increase renal damage; therefore, an 
echocardiogram and fluoroscopy-guided procedure, using the calcified contours 
of the stenotic aortic valve as a landmark may be a useful alternative. We report 
the first successful transfemoral aortic valve implantation procedure performed 
under fluoroscopy and transesophageal echocardiogram control, without 
administration of contrast medium injections in a patient with severe renal 
insufficiency and multiorgan failure.
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angiography showed a patent left circumflex 
coronary artery and right coronary artery and 
a thrombotic subocclusion of the drug-eluting 
stent in the mid LAD artery with TIMI 2 flow. 
Aortic–iliac angiography showed moderately 
tortouse and calcified arteries. Percutaneous 
coronary intervention was not performed as 
the amount of contrast media given was near 
to the 4 ml/kg limit and was not under dial-
ysis [10]. After 3 days, although signs of renal 
and liver failure persisted, after hemodynamic 
stabilization, balloon percutaneous coronary 
intervention of the LAD artery was performed. 
During a 2-week stay, the patient had two 
episodes of pulmonary edema with hyper tensive 
peaks. Aortic gradient, however, increased from 
5 mmHg after valvuloplasty to 20 mmHg sug-
gesting both a partial valve recoil and left ven-
tricular ejection fraction improvement. The 
heart team was consulted for the definite treat-
ment of the aortic valve stenosis. In view of a 
comorbidities and high logistic EuroScore of 
68% the heart team decided for a transfemoral 
transcatheter aortic valve implantation (TAVI), 
which was accepted by the patient.
The procedure was performed under general 
anesthesia through a surgically explored right 
femoral artery. A 12° cranial 10° left anterior 
oblique projection obtained by angiography at 
the time of the emergency valvuloplasty was 
selected to properly visualize the aortic valve 
(Figure 1A). The aortic annulus diameter was 
21 mm with TEE intraoperatively (Figure 2A). 
A pigtail catheter was placed in the ascending 
aorta for emergency, procedure saving contrast 
injection. The aortic valve was crossed and a 
balloon valvuloplasty with a 20-mm balloon 
was performed under rapid pacing and TEE 
monitoring (Figure 1B). After a 23-mm Edwards 
SAPIEN XT transcatheter valve, with Nova 
Flex® transfemoral delivering system (Edwards 
Life sciences Inc., CA, USA) was implanted 
under f luoroscopy control, using an aortic 
annulus calcifications as landmarks (Figure 1C) 
and TEE imaging (Figure 2B).
After valve deployment under rapid pac-
ing (Figure 1D), the TEE confirmed the cor-
rect valve placement with a peak gradient of 
10 mmHg and minimal of paravalvular leak-
age (Figure 2C & D). No contrast media was given 
during the whole procedure. The vascular access 
was closed surgically.
Immediate postintervention recovery was 
uneventful with on-table extubation. The 
postoperative serum creatinine level was stable 
(1.9 mg/dl on day 1, 1.6 mg/dl on day 2 and 
1.5 mg/dl on day 3) and an echocardiogram 
confirmed an aortic peak and mean gradient 
of 10 mmHg and 7 mmHg, respectively, with 
minimal paravalvular leakage.
During the following days, the patient had 
marked improvement in liver and renal func-
tion and no ischemic changes in the ECG. The 
patient was transferred to a rehabilitation center 
in stable condition. 
Discussion
The present case demonstrates the feasibility 
of guiding TF-AVI with fluoroscopy and TEE 
without administration of contrast media, and 
may represent an advancement of the possibilities 
offered by the TAVI procedure in patients with 
renal insufficiency.
Indeed, recently published reports have shown 
an incidence of postoperative renal failure in as 
many as 30% of cases, often requiring transitory 
or permanent dialysis [3,4]. The average contrast 
medium dose given during a standard TAVI pro-
cedure is 100–300 ml [1], a volume that may prove 
deleterious in old and fragile patients [4] and even 
increase the risk of postoperative mortality [5], 
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Figure 1. Fluoroscopic aortic valve prosthesis deployment. 
(A) Pretranscatheter aortic valve implantation aortogram in left anterior oblique 
projection of fluoroscopy: 10° and cranial: 12° showing tricuspid aortic valve with 
minimal regurgitation. (B) Balloon valvuloplasty before implantation of aortic valve 
prosthesis. (C) Positioning of aortic valve prosthesis taking aortic valve calcification 
as landmark (arrow). (D) Deployment of aortic valve prosthesis under rapid spacing.
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which may be excluded from the procedure 
because of renal dysfunction as demonstrated in 
the PARTNER trial [6].
In order to minimize contrast-induced renal 
damage in a patient with pre-existing renal fail-
ure, we successfully attempted a totally fluoro-
scopy and echocardiogram-guided TF-AVI 
without contrast medium, obtaining almost 
complete return to acceptable creatinine val-
ues after normalization of the hemodynamic 
status. Previous experiences using transapical 
TAVI without administration of contrast media 
are available [7,8] but this is, to our knowledge, 
the first reported case performed from the 
femoral access.
The rationale of performing a TF-AVI with-
out or with minimum administration of contrast 
medium (if absolutely needed) should be evalu-
ated in the context of extremely critical clinical 
situations such as the one reported here, in which 
we demonstrate the feasibility of this option. 
More reports are required to further analyze this 
technique.
Executive summary
 n Transcatheter aortic valve implantation (TAVI) is widely accepted as viable technique in high-risk aortic stenosis patients.
 n The patients undergoing TAVI usually suffering from severe comorbite conditions perhaps chronic renal failure is frequent.
 n Several contrast injections are needed before and after prosthesis deployment during TAVI especially during a transfemoral TAVI. 
Furthermore, a recently published clinical trail described a contrast administration in chronic renal failure during TAVI increase risk of 
acute postoperative renal failure.
 n Transesophgeal echocardiography and fluoroscopy may be useful option in these patients for proper deployment of prosthesis.
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Figure 2. Transesophageal echocardiographic aortic valve prosthesis deployment. 
(A) Transesophageal echocardiography showing severely calcified tricuspid aortic valve before 
transcatheter aortic-valve implantation. (B) Positioning of aortic valve prosthesis under echo 
guidance. (C) Transesophageal echocardiography short axis of implanted aortic valve prosthesis. 
(D) Transesophageal echocardiography long axis of implanted aortic valve prosthesis showing mild 
peripheral aortic regurgitation.
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